Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors

There have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewe...

Full description

Bibliographic Details
Main Authors: Masaya Iwamuro, Koji Miyahara, Chihiro Sakaguchi, Ryuta Takenaka, Sayo Kobayashi, Hirokazu Mouri, Shigetomi Tanaka, Tatsuya Toyokawa, Shouichi Tanaka, Mamoru Nishimura, Kenji Yamauchi, Takehiro Tanaka, Hiroyuki Okada
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/9/5/1301
id doaj-6cbb63808a7b42309b9c45cad20e101e
record_format Article
spelling doaj-6cbb63808a7b42309b9c45cad20e101e2020-11-25T02:34:37ZengMDPI AGJournal of Clinical Medicine2077-03832020-05-0191301130110.3390/jcm9051301Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal TumorsMasaya Iwamuro0Koji Miyahara1Chihiro Sakaguchi2Ryuta Takenaka3Sayo Kobayashi4Hirokazu Mouri5Shigetomi Tanaka6Tatsuya Toyokawa7Shouichi Tanaka8Mamoru Nishimura9Kenji Yamauchi10Takehiro Tanaka11Hiroyuki Okada12Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, JapanDepartment of Internal Medicine, Hiroshima City Hospital, Hiroshima 730-8518, JapanDepartment of Endoscopy, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, JapanDepartment of Internal Medicine, Tsuyama Chuo Hospital, Tsuyama 708-0841, JapanDepartment of Internal Medicine, Fukuyama City Hospital, Fukuyama 721-8511, JapanDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, Okayama 710-8602, JapanDepartment of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu 760-8557, JapanDepartment of Gastroenterology, Fukuyama Medical Center, Fukuyama 720-8520, JapanDepartment of Gastroenterology, Iwakuni Clinical Center, Iwakuni, Yamaguchi 740-8510, JapanDepartment of Internal Medicine, Okayama City Hospital, Okayama 700-0962, JapanDepartment of Gastroenterology, Mitoyo General Hospital, Kan-onji 769-1695, JapanDepartment of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, JapanDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, JapanThere have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewed the data of 142 patients with pathologically diagnosed gastric mesenchymal tumors treated at 11 institutions. We analyzed the correlation between the maximum standardized uptake value (SUVmax) evaluated using fluorodeoxyglucose-positron emission tomography (FDG-PET) and the tumor size. The correlation between the SUVmax and mitotic index was also investigated in GISTs. The SUVmax (mean ± standard deviation) was 0.5 ± 0.6 in very low-risk GISTs (<i>n</i> = 42), 2.1 ± 0.7 in low-risk GISTs (<i>n</i> = 26), 4.9 ± 0.8 in intermediate-risk GISTs (<i>n</i> = 22), 12.3 ± 0.8 in high-risk GISTs (<i>n</i> = 20), 1.0 ± 1.0 in leiomyomas (<i>n</i> = 15), 6.9 ± 1.2 in schwannomas (<i>n</i> = 10), and 3.5 in a leiomyosarcoma (<i>n</i> = 1). The SUVmax of GISTs with an undetermined risk classification was 4.2 ± 1.3 (<i>n</i> = 8). Linear associations were observed between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax of GISTs with a high mitotic index was significantly higher than that of GISTs with a low mitotic index (9.6 ± 7.6 vs. 2.4 ± 4.2). In conclusion, we observed positive correlations between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax also positively correlated with the mitotic index and risk grade in GISTs. Schwannomas showed a higher FDG uptake than GISTs and leiomyomas.https://www.mdpi.com/2077-0383/9/5/130118F-fluorodeoxyglucose-positron emission tomographymesenchymal tumorgastric neoplasmsgastrointestinal stromal tumorschwannoma
collection DOAJ
language English
format Article
sources DOAJ
author Masaya Iwamuro
Koji Miyahara
Chihiro Sakaguchi
Ryuta Takenaka
Sayo Kobayashi
Hirokazu Mouri
Shigetomi Tanaka
Tatsuya Toyokawa
Shouichi Tanaka
Mamoru Nishimura
Kenji Yamauchi
Takehiro Tanaka
Hiroyuki Okada
spellingShingle Masaya Iwamuro
Koji Miyahara
Chihiro Sakaguchi
Ryuta Takenaka
Sayo Kobayashi
Hirokazu Mouri
Shigetomi Tanaka
Tatsuya Toyokawa
Shouichi Tanaka
Mamoru Nishimura
Kenji Yamauchi
Takehiro Tanaka
Hiroyuki Okada
Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors
Journal of Clinical Medicine
18F-fluorodeoxyglucose-positron emission tomography
mesenchymal tumor
gastric neoplasms
gastrointestinal stromal tumor
schwannoma
author_facet Masaya Iwamuro
Koji Miyahara
Chihiro Sakaguchi
Ryuta Takenaka
Sayo Kobayashi
Hirokazu Mouri
Shigetomi Tanaka
Tatsuya Toyokawa
Shouichi Tanaka
Mamoru Nishimura
Kenji Yamauchi
Takehiro Tanaka
Hiroyuki Okada
author_sort Masaya Iwamuro
title Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors
title_short Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors
title_full Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors
title_fullStr Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors
title_full_unstemmed Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors
title_sort diagnostic role of 18f-fluorodeoxyglucose positron emission tomography in gastric mesenchymal tumors
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2020-05-01
description There have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewed the data of 142 patients with pathologically diagnosed gastric mesenchymal tumors treated at 11 institutions. We analyzed the correlation between the maximum standardized uptake value (SUVmax) evaluated using fluorodeoxyglucose-positron emission tomography (FDG-PET) and the tumor size. The correlation between the SUVmax and mitotic index was also investigated in GISTs. The SUVmax (mean ± standard deviation) was 0.5 ± 0.6 in very low-risk GISTs (<i>n</i> = 42), 2.1 ± 0.7 in low-risk GISTs (<i>n</i> = 26), 4.9 ± 0.8 in intermediate-risk GISTs (<i>n</i> = 22), 12.3 ± 0.8 in high-risk GISTs (<i>n</i> = 20), 1.0 ± 1.0 in leiomyomas (<i>n</i> = 15), 6.9 ± 1.2 in schwannomas (<i>n</i> = 10), and 3.5 in a leiomyosarcoma (<i>n</i> = 1). The SUVmax of GISTs with an undetermined risk classification was 4.2 ± 1.3 (<i>n</i> = 8). Linear associations were observed between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax of GISTs with a high mitotic index was significantly higher than that of GISTs with a low mitotic index (9.6 ± 7.6 vs. 2.4 ± 4.2). In conclusion, we observed positive correlations between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax also positively correlated with the mitotic index and risk grade in GISTs. Schwannomas showed a higher FDG uptake than GISTs and leiomyomas.
topic 18F-fluorodeoxyglucose-positron emission tomography
mesenchymal tumor
gastric neoplasms
gastrointestinal stromal tumor
schwannoma
url https://www.mdpi.com/2077-0383/9/5/1301
work_keys_str_mv AT masayaiwamuro diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT kojimiyahara diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT chihirosakaguchi diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT ryutatakenaka diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT sayokobayashi diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT hirokazumouri diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT shigetomitanaka diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT tatsuyatoyokawa diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT shouichitanaka diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT mamorunishimura diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT kenjiyamauchi diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT takehirotanaka diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
AT hiroyukiokada diagnosticroleof18ffluorodeoxyglucosepositronemissiontomographyingastricmesenchymaltumors
_version_ 1724807795265503232